Acceleron Pharma Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Acceleron Pharma's estimated annual revenue is currently $62.1M per year.
- Acceleron Pharma received $264.5M in venture funding in January 2019.
- Acceleron Pharma's estimated revenue per employee is $201,000
- Acceleron Pharma's total funding is $141.7M.
- Acceleron Pharma has 309 Employees.
- Acceleron Pharma grew their employee count by 13% last year.
- Acceleron Pharma currently has 35 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Acceleron Pharma?
Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair. Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.keywords:Biotechnology,Cleantech,E-Commerce,Healthcare,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
Acceleron Pharma News
In 2016 Habib Dable was appointed CEO of Acceleron Pharma Inc. (NASDAQ:XLRN). This report will, first, examine the CEO compensation ...
On August 19, 2019, Acceleron Pharma Inc. (NASDAQ:XLRN) shares gained 1.11% or 0.51 points to close at $46.51 with a thin trading volume ...
Los Angeles Capital Management & Equity Research Inc. cut its stake in Acceleron Pharma Inc (NASDAQ:XLRN) by 20.5% in the second ...
Acceleron Pharma Funding
|2004-02-16||$25.0M||1st||Polaris Venture Partners||Article|
|2006-01-06||$8.0M||Undisclosed||Hercules Technology Growth Cap||Article|
|2007-10-31||$31.0M||C||Bessemer Venture Partners||Article|
|2017-09-22||$230.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
Acceleron Pharma Executive Hires
|2006-05-17||Matthew L. Sherman||Chief Medical Officer||Article|
|2007-03-30||Robert Steininger||SVP Manufacturing||Article|
|2007-04-26||James Desiderio||VP Program Mgmt||Article|
|2007-09-19||John L. Knopf||CEO||Article|
|2007-09-25||Niels Borgstein||VP Medical Research||Article|
|2009-12-23||Melissa Morandi||VP Quality||Article|
|2010-12-01||Kevin F. McLaughlin||SVP/CFO||Article|
|2017-05-03||Steven Ertel||Special Aadvisor||Article|
|2018-02-09||Sujay Kango||Chief Commercial Officer||Article|
|2018-07-06||Robert Zeldin||Chief Medical Officer||Article|
Acceleron Pharma Staff Cuts
|Date||Number of Employees||Location||Reference|